

Erik S G Stroes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2181865/publications.pdf>

Version: 2024-02-01

175
papers

23,528
citations

19657

61
h-index

7950

149
g-index

180
all docs

180
docs citations

180
times ranked

20842
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188. | 2.2 | 4,871 |
| 2 | Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2013, 34, 3478-3490. | 2.2 | 2,132 |
| 3 | Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. <i>New England Journal of Medicine</i> , 2008, 358, 1431-1443. | 27.0 | 1,180 |
| 4 | Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , 2015, 36, 1012-1022. | 2.2 | 1,024 |
| 5 | Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. <i>European Heart Journal</i> , 2014, 35, 2146-2157. | 2.2 | 835 |
| 6 | Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. <i>Circulation</i> , 2019, 139, 1483-1492. | 1.6 | 533 |
| 7 | The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 655-666. | 11.4 | 473 |
| 8 | Loss of Endothelial Glycocalyx During Acute Hyperglycemia Coincides With Endothelial Dysfunction and Coagulation Activation In Vivo. <i>Diabetes</i> , 2006, 55, 480-486. | 0.6 | 469 |
| 9 | Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2541-2548. | 2.8 | 465 |
| 10 | Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. <i>Journal of the American College of Cardiology</i> , 2005, 45, 185-197. | 2.8 | 402 |
| 11 | Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. <i>Circulation</i> , 2016, 134, 611-624. | 1.6 | 396 |
| 12 | Endothelial Glycocalyx Damage Coincides With Microalbuminuria in Type 1 Diabetes. <i>Diabetes</i> , 2006, 55, 1127-1132. | 0.6 | 361 |
| 13 | Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. <i>New England Journal of Medicine</i> , 2019, 381, 531-542. | 27.0 | 359 |
| 14 | A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. <i>Nature Communications</i> , 2014, 5, 3065. | 12.8 | 336 |
| 15 | Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1780. | 7.4 | 314 |
| 16 | Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. <i>European Heart Journal</i> , 2021, 42, 4791-4806. | 2.2 | 303 |
| 17 | Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. <i>Diabetologia</i> , 2010, 53, 2646-2655. | 6.3 | 302 |
| 18 | Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. <i>Journal of the American Heart Association</i> , 2019, 8, e011662. | 3.7 | 292 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Microthrombosis after Aneurysmal Subarachnoid Hemorrhage: An Additional Explanation for Delayed Cerebral Ischemia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008, 28, 1761-1770. | 4.3 | 289 |
| 20 | Restoration of Endothelial Function by Increasing High-Density Lipoprotein in Subjects With Isolated Low High-Density Lipoprotein. <i>Circulation</i> , 2003, 107, 2944-2948. | 1.6 | 283 |
| 21 | Folic Acid Reverts Dysfunction of Endothelial Nitric Oxide Synthase. <i>Circulation Research</i> , 2000, 86, 1129-1134. | 4.5 | 265 |
| 22 | Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. <i>Circulation</i> , 2020, 142, 621-642. | 1.6 | 232 |
| 23 | Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 593-603. | 1.8 | 224 |
| 24 | Activation of Inflammation and Coagulation After Infusion of C-Reactive Protein in Humans. <i>Circulation Research</i> , 2005, 96, 714-716. | 4.5 | 208 |
| 25 | Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2150-2162. | 2.8 | 187 |
| 26 | Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. <i>Science Advances</i> , 2015, 1, . | 10.3 | 173 |
| 27 | Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. <i>European Heart Journal</i> , 2012, 33, 1142-1149. | 2.2 | 171 |
| 28 | Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability. <i>Journal of Applied Physiology</i> , 2008, 104, 845-852. | 2.5 | 170 |
| 29 | Effect of Vegan Fecal Microbiota Transplantation on Carnitine and Choline Derived Trimethylamine N-Oxide Production and Vascular Inflammation in Patients With Metabolic Syndrome. <i>Journal of the American Heart Association</i> , 2018, 7, . | 3.7 | 164 |
| 30 | Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 473-483. | 2.6 | 160 |
| 31 | Oral treatment with <i>Eubacterium hallii</i> improves insulin sensitivity in db/db mice. <i>Npj Biofilms and Microbiomes</i> , 2016, 2, 16009. | 6.4 | 159 |
| 32 | Influence of Folic Acid on Postprandial Endothelial Dysfunction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 185-188. | 2.4 | 150 |
| 33 | PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia. <i>European Heart Journal</i> , 2017, 38, 1584-1593. | 2.2 | 141 |
| 34 | Lipoprotein Lipase S447X. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1236-1245. | 2.4 | 140 |
| 35 | Role of the Apolipoprotein B/Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A Case-Control Analysis in EPIC-Norfolk. <i>Annals of Internal Medicine</i> , 2007, 146, 640. | 3.9 | 140 |
| 36 | Safety and Tolerability of Dalcetrapib Conflicts of interest: Dr. Stein has received grants for studies of lipid-modifying agents, has received consulting fees and honoraria for professional input regarding agents to modify lipid profile, and/or has delivered lectures for the American Association for Clinical Chemistry, Washington, District of Columbia; Abbott Laboratories, Abbott Park, Illinois; AstraZeneca, Wilmington, Delaware; the United States Food and Drug Administration, Washington, District of Colu. <i>American Journal of Cardiology</i> , 2009, 104, 82-91. | 1.6 | 134 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". <i>Atherosclerosis</i> , 2018, 275, 265-272. | 0.8 | 131 |
| 38 | Treatment with Statins Does Not Revert Trained Immunity in Patients with Familial Hypercholesterolemia. <i>Cell Metabolism</i> , 2019, 30, 1-2. | 16.2 | 130 |
| 39 | Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. <i>European Journal of Clinical Investigation</i> , 2002, 32, 9-16. | 3.4 | 129 |
| 40 | A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1429-1435. | 2.8 | 124 |
| 41 | Biologic Effects of Simvastatin in Patients with Aneurysmal Subarachnoid Hemorrhage: A Double-Blind, Placebo-Controlled Randomized Trial. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 1444-1453. | 4.3 | 118 |
| 42 | Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 264-275. | 11.4 | 109 |
| 43 | High-Density Lipoprotein Attenuates Inflammation and Coagulation Response on Endotoxin Challenge in Humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 1153-1158. | 2.4 | 102 |
| 44 | Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. <i>European Heart Journal</i> , 2018, 39, 2589-2596. | 2.2 | 100 |
| 45 | Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation. <i>Circulation Research</i> , 2020, 126, 1346-1359. | 4.5 | 96 |
| 46 | Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. <i>European Heart Journal</i> , 2019, 40, 2775-2781. | 2.2 | 95 |
| 47 | Diagnostic algorithm for familial chylomicronemia syndrome. <i>Atherosclerosis Supplements</i> , 2017, 23, 1-7. | 1.2 | 94 |
| 48 | Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. <i>Nature Biomedical Engineering</i> , 2018, 2, 279-292. | 22.5 | 94 |
| 49 | Combination lipid-lowering therapy as first-line strategy in very high-risk patients. <i>European Heart Journal</i> , 2022, 43, 830-833. | 2.2 | 92 |
| 50 | Nonpharmacological Lipoprotein Apheresis Reduces Arterial Inflammation in Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1418-1426. | 2.8 | 90 |
| 51 | Remnant Cholesterol Elicits Arterial Wall Inflammation and a Multilevel Cellular Immune Response in Humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 969-975. | 2.4 | 85 |
| 52 | Thresholds for Arterial Wall Inflammation Quantified by 18F-FDG PET Imaging. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 1198-1207. | 5.3 | 81 |
| 53 | Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease. <i>Circulation</i> , 2020, 142, 1996-1998. | 1.6 | 81 |
| 54 | Perturbation of hyaluronan metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis. <i>Diabetologia</i> , 2007, 50, 1288-1293. | 6.3 | 80 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | In Vivo PET Imaging of HDL in Multiple Atherosclerosis Models. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 950-961. | 5.3 | 78 |
| 56 | Current therapies for lowering lipoprotein (a). <i>Journal of Lipid Research</i> , 2016, 57, 1612-1618. | 4.2 | 77 |
| 57 | Efficacy and Safety of Alirocumab 150mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. <i>Journal of the American Heart Association</i> , 2016, 5, . | 3.7 | 71 |
| 58 | Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention. <i>European Heart Journal</i> , 2020, 41, 3998-4007. | 2.2 | 68 |
| 59 | FISHing for the Miracle of Eicosapentaenoic Acid. <i>New England Journal of Medicine</i> , 2019, 380, 89-90. | 27.0 | 66 |
| 60 | Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). <i>European Heart Journal</i> , 2020, 41, 2262-2271. | 2.2 | 65 |
| 61 | Pharmacokinetics and Pharmacodynamics of Combined use of Lopinavir/Ritonavir and Rosuvastatin in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2007, 12, 1127-1132. | 1.0 | 64 |
| 62 | From design to the clinic: practical guidelines for translating cardiovascular nanomedicine. <i>Cardiovascular Research</i> , 2018, 114, 1714-1727. | 3.8 | 63 |
| 63 | Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus. <i>Diabetologia</i> , 2008, 51, 1081-1084. | 6.3 | 62 |
| 64 | Increased haematopoietic activity in patients with atherosclerosis. <i>European Heart Journal</i> , 2016, 38, ehw246. | 2.2 | 62 |
| 65 | ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden. <i>European Heart Journal</i> , 2013, 34, 286-291. | 2.2 | 61 |
| 66 | Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia. <i>Journal of the American Heart Association</i> , 2017, 6, . | 3.7 | 61 |
| 67 | Oral butyrate does not affect innate immunity and islet autoimmunity in individuals with longstanding type 1 diabetes: a randomised controlled trial. <i>Diabetologia</i> , 2020, 63, 597-610. | 6.3 | 60 |
| 68 | The Pharmacology and Off-Target Effects of Some Cholesterol Ester Transfer Protein Inhibitors. <i>American Journal of Cardiology</i> , 2009, 104, 32E-38E. | 1.6 | 59 |
| 69 | Cholesterol Acyltransferase Gene Mutations Have Accelerated Atherogenesis as Assessed by Carotid 3.0-T Magnetic Resonance Imaging. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2481-2487. | 2.8 | 58 |
| 70 | Targeted proteomics improves cardiovascular risk prediction in secondary prevention. <i>European Heart Journal</i> , 2022, 43, 1569-1577. | 2.2 | 55 |
| 71 | Intestinal <i>Ralstonia pickettii</i> augments glucose intolerance in obesity. <i>PLoS ONE</i> , 2017, 12, e0181693. | 2.5 | 53 |
| 72 | The dedicated 'Lp(a) clinic': A concept whose time has arrived?. <i>Atherosclerosis</i> , 2020, 300, 1-9. | 0.8 | 52 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Nitric oxide and hypercholesterolemia: a matter of oxidation and reduction?. <i>Atherosclerosis</i> , 1998, 137, S51-S60. | 0.8 | 51 |
| 74 | Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats. <i>British Journal of Pharmacology</i> , 2009, 158, 1763-1770. | 5.4 | 48 |
| 75 | Monocyte-Chemoattractant Protein-1 Levels in Human Atherosclerotic Lesions Associate With Plaque Vulnerability. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2038-2048. | 2.4 | 48 |
| 76 | Physical activity, metabolic syndrome, and coronary risk: the EPIC-Norfolk prospective population study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 209-217. | 2.8 | 46 |
| 77 | Arterial and Cellular Inflammation in Patients with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1278-1285. | 6.1 | 46 |
| 78 | Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 948-955. | 1.8 | 46 |
| 79 | Statins and LDL-cholesterol lowering: an overview. <i>Current Medical Research and Opinion</i> , 2005, 21, S9-S16. | 1.9 | 45 |
| 80 | Mycophenolate mofetil (MMF): Firing at the atherosclerotic plaque from different angles?. <i>Cardiovascular Research</i> , 2006, 69, 341-347. | 3.8 | 45 |
| 81 | High density lipoprotein as a source of cholesterol for adrenal steroidogenesis: a study in individuals with low plasma HDL-C. <i>Journal of Lipid Research</i> , 2013, 54, 1698-1704. | 4.2 | 45 |
| 82 | PCSK9 inhibitors in clinical practice: Delivering on the promise?. <i>Atherosclerosis</i> , 2018, 270, 205-210. | 0.8 | 45 |
| 83 | Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases. <i>European Heart Journal</i> , 2018, 39, 3521-3527. | 2.2 | 44 |
| 84 | PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2571-2573. | 5.3 | 44 |
| 85 | CCR2 expression on circulating monocytes is associated with arterial wall inflammation assessed by 18F-FDG PET/CT in patients at risk for cardiovascular disease. <i>Cardiovascular Research</i> , 2018, 114, 468-475. | 3.8 | 43 |
| 86 | Predictive value of targeted proteomics for coronary plaque morphology in patients with suspected coronary artery disease. <i>EBioMedicine</i> , 2019, 39, 109-117. | 6.1 | 42 |
| 87 | Novel anti-inflammatory strategies in atherosclerosis. <i>Current Opinion in Lipidology</i> , 2012, 23, 532-539. | 2.7 | 39 |
| 88 | Measurement of subclinical atherosclerosis: beyond risk factor assessment. <i>Current Opinion in Lipidology</i> , 2002, 13, 595-603. | 2.7 | 37 |
| 89 | Inhibition of hepatic sulfatase-2 In Vivo: A novel strategy to correct diabetic dyslipidemia. <i>Hepatology</i> , 2012, 55, 1746-1753. | 7.3 | 37 |
| 90 | Pharmaceutical development and preclinical evaluation of a GMP-grade anti-inflammatory nanotherapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1133-1140. | 3.3 | 37 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | Comparison between Gradient Gel Electrophoresis and Nuclear Magnetic Resonance Spectroscopy in Estimating Coronary Heart Disease Risk Associated with LDL and HDL Particle Size. <i>Clinical Chemistry</i> , 2010, 56, 789-798. | 3.2 | 36 |
| 92 | Cardiovascular risk factors and COVID-19 outcomes in hospitalised patients: a prospective cohort study. <i>BMJ Open</i> , 2021, 11, e045482. | 1.9 | 35 |
| 93 | Marked plaque regression in homozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , 2021, 327, 13-17. | 0.8 | 35 |
| 94 | Effects of an Antisense Oligonucleotide Inhibitor of C-reactive Protein Synthesis on the Endotoxin Challenge Response in Healthy Human Male Volunteers. <i>Journal of the American Heart Association</i> , 2014, 3, . | 3.7 | 33 |
| 95 | Liposomal prednisolone promotes macrophage lipotoxicity in experimental atherosclerosis. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 1463-1470. | 3.3 | 32 |
| 96 | Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-intolerant Subjects 3 (GAUSS-3) Trial. <i>Clinical Cardiology</i> , 2016, 39, 137-144. | 1.8 | 32 |
| 97 | Lipoprotein(a): An underestimated inflammatory mastermind. <i>Atherosclerosis</i> , 2022, 349, 101-109. | 0.8 | 32 |
| 98 | Patients with low HDL-cholesterol caused by mutations in LCAT have increased arterial stiffness. <i>Atherosclerosis</i> , 2012, 225, 481-485. | 0.8 | 31 |
| 99 | Impact of cholesterol on proinflammatory monocyte production by the bone marrow. <i>European Heart Journal</i> , 2021, 42, 4309-4320. | 2.2 | 31 |
| 100 | The Effect of a Diiodothyronine Mimetic on Insulin Sensitivity in Male Cardiometabolic Patients: A Double-Blind Randomized Controlled Trial. <i>PLoS ONE</i> , 2014, 9, e86890. | 2.5 | 30 |
| 101 | Unexpected arterial wall and cellular inflammation in patients with rheumatoid arthritis in remission using biological therapy: a cross-sectional study. <i>Arthritis Research and Therapy</i> , 2016, 18, 115. | 3.5 | 30 |
| 102 | Inhibition of PFKFB3 Hampers the Progression of Atherosclerosis and Promotes Plaque Stability. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 581641. | 3.7 | 29 |
| 103 | Finding very high lipoprotein(a): the need for routine assessment. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 769-776. | 1.8 | 29 |
| 104 | Inflammation-Sensitive Myosin-X Functionally Supports Leukocyte Extravasation by Cdc42-Mediated ICAM-1-Rich Endothelial Filopodia Formation. <i>Journal of Immunology</i> , 2018, 200, 1790-1801. | 0.8 | 28 |
| 105 | Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema. <i>New England Journal of Medicine</i> , 2020, 383, 1242-1247. | 27.0 | 28 |
| 106 | Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study. <i>Atherosclerosis</i> , 2022, 341, 43-49. | 0.8 | 28 |
| 107 | Lipid Oxidation in Carriers of Lecithin:Cholesterol Acyltransferase Gene Mutations. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 3066-3075. | 2.4 | 27 |
| 108 | Association of Long-term Exposure to Elevated Lipoprotein(a) Levels With Parental Life Span, Chronic Disease-Free Survival, and Mortality Risk. <i>JAMA Network Open</i> , 2020, 3, e200129. | 5.9 | 27 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Increased arterial wall inflammation in patients with ankylosing spondylitis is reduced by statin therapy. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1848-1851. | 0.9 | 26 |
| 110 | Design and Rationale of the GAUSS-2 Study Trial: A Double-Blind, Ezetimibe-Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (AMG 145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy. <i>Clinical Cardiology</i> , 2014, 37, 131-139. | 1.8 | 25 |
| 111 | Consistent LDL response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. <i>Clinical Cardiology</i> , 2018, 41, 1328-1335. | 1.8 | 25 |
| 112 | BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes. <i>Clinical Epigenetics</i> , 2020, 12, 166. | 4.1 | 25 |
| 113 | Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 355-361. | 1.5 | 25 |
| 114 | The Promise of Cholesteryl Ester Transfer Protein (CETP) Inhibition in the Treatment of Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2013, 19, 3143-3149. | 1.9 | 24 |
| 115 | How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL. <i>Atherosclerosis Supplements</i> , 2017, 26, 16-24. | 1.2 | 24 |
| 116 | HDL does not influence the polarization of human monocytes toward an alternative phenotype. <i>International Journal of Cardiology</i> , 2014, 172, 179-184. | 1.7 | 23 |
| 117 | Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 297-304. | 2.6 | 23 |
| 118 | Magnetic Resonance Imaging-Derived Renal Oxygenation and Perfusion During Continuous, Steady-State Angiotensin-II Infusion in Healthy Humans. <i>Journal of the American Heart Association</i> , 2016, 5, e003185. | 3.7 | 23 |
| 119 | C-reactive Protein Identifies Low-Risk Metabolically Healthy Obese Persons: The European Prospective Investigation of Cancer-Norfolk Prospective Population Study. <i>Journal of the American Heart Association</i> , 2016, 5, . | 3.7 | 23 |
| 120 | Next-generation sequencing to confirm clinical familial hypercholesterolemia. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 875-883. | 1.8 | 23 |
| 121 | Pharmaceutical Development and Safety Evaluation of a GMP-Grade Fucoidan for Molecular Diagnosis of Cardiovascular Diseases. <i>Marine Drugs</i> , 2019, 17, 699. | 4.6 | 22 |
| 122 | Multimodal Positron Emission Tomography Imaging to Quantify Uptake of ⁸⁹ Zr-Labeled Liposomes in the Atherosclerotic Vessel Wall. <i>Bioconjugate Chemistry</i> , 2020, 31, 360-368. | 3.6 | 22 |
| 123 | No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. <i>Atherosclerosis</i> , 2020, 311, 13-19. | 0.8 | 21 |
| 124 | How common are foot problems among individuals with diabetes? Diabetic foot ulcers in the Dutch population. <i>Diabetologia</i> , 2017, 60, 1271-1275. | 6.3 | 20 |
| 125 | Nile Red Quantifier: a novel and quantitative tool to study lipid accumulation in patient-derived circulating monocytes using confocal microscopy. <i>Journal of Lipid Research</i> , 2017, 58, 2210-2219. | 4.2 | 20 |
| 126 | Gene-based therapy in lipid management: the winding road from promise to practice. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 483-493. | 4.1 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 365-372. | 2.6 | 19 |
| 128 | Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis. <i>Heart</i> , 2022, 108, 61-66. | 2.9 | 18 |
| 129 | New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 119-127. | 3.0 | 17 |
| 130 | Netrin-1 and the Grade of Atherosclerosis Are Inversely Correlated in Humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 462-472. | 2.4 | 17 |
| 131 | Characterization of immune cell, endothelial, and renal responses upon experimental human endotoxemia. <i>Journal of Pharmacological and Toxicological Methods</i> , 2018, 89, 39-46. | 0.7 | 16 |
| 132 | Elevated Lp(a) (Lipoprotein[a]) Levels Increase Risk of 30-Day Major Adverse Cardiovascular Events in Patients Following Carotid Endarterectomy. <i>Stroke</i> , 2020, 51, 2972-2982. | 2.0 | 16 |
| 133 | Extreme xanthomatosis in patients with both familial hypercholesterolemia and cerebrotendinous xanthomatosis. <i>Clinical Genetics</i> , 2012, 81, 24-28. | 2.0 | 14 |
| 134 | Dynamic magnetic resonance measurements of calf muscle oxygenation and energy metabolism in peripheral artery disease. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 98-107. | 3.4 | 13 |
| 135 | Adrenal Function in Females with Low Plasma HDL-C Due to Mutations in ABCA1 and LCAT. <i>PLoS ONE</i> , 2014, 9, e90967. | 2.5 | 12 |
| 136 | HDL infusion for the management of atherosclerosis. <i>Current Opinion in Lipidology</i> , 2016, 27, 592-596. | 2.7 | 12 |
| 137 | Next-generation sequencing to confirm clinical familial hypercholesterolemia. <i>European Journal of Preventive Cardiology</i> , 2020, , 204748732094299. | 1.8 | 12 |
| 138 | Carriers of Loss-of-Function Mutations in EXT Display Impaired Pancreatic Beta-Cell Reserve Due to Smaller Pancreas Volume. <i>PLoS ONE</i> , 2014, 9, e115662. | 2.5 | 12 |
| 139 | Lipoprotein(a) Induces Vesicular Cardiovascular Calcification Revealed With Single-Extracellular Vesicle Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 778919. | 2.4 | 12 |
| 140 | Lipid Measures and Cardiovascular Disease Prediction. <i>Disease Markers</i> , 2009, 26, 209-216. | 1.3 | 11 |
| 141 | Sex-Specific Associations of Genetically Predicted Circulating Lp(a) (Lipoprotein(a)) and Hepatic <i>LPA</i> Gene Expression Levels With Cardiovascular Outcomes: Mendelian Randomization and Observational Analyses. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003271. | 3.6 | 11 |
| 142 | Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease?. <i>Cardiovascular Research</i> , 1998, 39, 543-549. | 3.8 | 9 |
| 143 | Impact of the B Cell Growth Factor APRIL on the Qualitative and Immunological Characteristics of Atherosclerotic Plaques. <i>PLoS ONE</i> , 2016, 11, e0164690. | 2.5 | 9 |
| 144 | Common gene variants in ASGR1 gene locus associate with reduced cardiovascular risk in absence of pleiotropic effects. <i>Atherosclerosis</i> , 2020, 306, 15-21. | 0.8 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Comparison of In Vivo Carotid 3.0-T Magnetic Resonance to B-Mode Ultrasound Imaging and Histology in a Porcine Model. <i>JACC: Cardiovascular Imaging</i> , 2009, 2, 744-750. | 5.3 | 8 |
| 146 | Increasing the Spatial Resolution of 3T Carotid MRI Has No Beneficial Effect for Plaque Component Measurement Reproducibility. <i>PLoS ONE</i> , 2015, 10, e0130878. | 2.5 | 8 |
| 147 | The maturation of a "neural" hematopoietic inflammatory axis in cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2017, 28, 507-512. | 2.7 | 8 |
| 148 | Carotid arterial wall inflammation in peripheral artery disease is augmented by type 2 diabetes: a cross-sectional study. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 237. | 1.7 | 7 |
| 149 | Prolonged hematopoietic and myeloid cellular response in patients after an acute coronary syndrome measured with 18F-DPA-714 PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1956-1963. | 6.4 | 7 |
| 150 | Antisense Apolipoprotein B-100 As Novel Treatment For Hypercholesterolemia: Focus On Isis 301012. <i>Future Lipidology</i> , 2007, 2, 387-393. | 0.5 | 6 |
| 151 | A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies. <i>Cardiology and Therapy</i> , 2020, 9, 447-465. | 2.6 | 6 |
| 152 | From evidence to practice: development of web-based Dutch lipid reference values. <i>Netherlands Heart Journal</i> , 2021, 29, 441-450. | 0.8 | 6 |
| 153 | PCSK9 Inhibition and Oxidized Phospholipids. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1288-1289. | 2.8 | 6 |
| 154 | Sulfated glycosaminoglycans restore glycocalyx barrier properties of cultured endothelial cells in hyperglycemia. <i>FASEB Journal</i> , 2008, 22, 83-83. | 0.5 | 6 |
| 155 | Effect of Anti-ApoA-I Antibody-Coating of Stents on Neointima Formation in a Rabbit Balloon-Injury Model. <i>PLoS ONE</i> , 2015, 10, e0122836. | 2.5 | 6 |
| 156 | Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemia. <i>Atherosclerosis</i> , 2022, 340, 61-67. | 0.8 | 6 |
| 157 | The challenge of choosing in cardiovascular risk management. <i>Netherlands Heart Journal</i> , 2022, 30, 47-57. | 0.8 | 5 |
| 158 | Guideline treatment results in regression of atherosclerosis in type 2 diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 126-132. | 2.0 | 4 |
| 159 | Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score. <i>Data in Brief</i> , 2018, 21, 1334-1336. | 1.0 | 4 |
| 160 | Sympathetic activation by lower body negative pressure decreases kidney perfusion without inducing hypoxia in healthy humans. <i>Clinical Autonomic Research</i> , 2020, 30, 149-156. | 2.5 | 4 |
| 161 | Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a). <i>Lipids in Health and Disease</i> , 2020, 19, 91. | 3.0 | 4 |
| 162 | Surmounting the endothelial barrier for delivery of drugs and imaging tracers. <i>Atherosclerosis</i> , 2020, 315, 93-101. | 0.8 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 163 | Considerations for routinely testing for high Lp(a). <i>Current Opinion in Lipidology</i> , 2022, 33, 213-218. | 2.7 | 4 |
| 164 | The therapeutic age paradox coming to an end. <i>European Heart Journal</i> , 2020, 41, 2259-2261. | 2.2 | 2 |
| 165 | Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease. <i>Scientific Reports</i> , 2021, 11, 4126. | 3.3 | 2 |
| 166 | Working towards full eradication of lipid-driven cardiovascular risk?. <i>Netherlands Heart Journal</i> , 2022, 30, 15-24. | 0.8 | 2 |
| 167 | Letter Regarding Article by Luo et al, "Adenovirus-Mediated Expression of Î²-Adrenergic Receptor Kinase C-Terminus Reduces Intimal Hyperplasia and Luminal Stenosis of Arteriovenous Polytetrafluoroethylene Grafts in Pigs". <i>Circulation</i> , 2005, 112, e153; author reply e153. | 1.6 | 1 |
| 168 | Dalceapib: turning the tide for CETP inhibition?. <i>Lancet</i> , 2011, 378, 1529-1530. | 13.7 | 1 |
| 169 | Reduced baroreflex sensitivity and increased splenic activity in patients with severe obstructive sleep apnea. <i>Atherosclerosis</i> , 2022, 344, 7-12. | 0.8 | 1 |
| 170 | PS3 - 15. Genetic Variation at the SULF2 Locus Affects Hepatic Postprandial Remnant Clearance in Patients with Type 2 Diabetes Mellitus. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2012, 10, 109-109. | 0.0 | 0 |
| 171 | PS14 - 68. Differential effects of antibiotics on bile acid metabolism, intestinal microbiota composition and insulin resistance in obese humans; a randomised controlled trial. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2012, 10, 147-147. | 0.0 | 0 |
| 172 | Hypertriglyceridemia: the future of genetics to guide individualized therapeutic strategies. <i>Clinical Lipidology</i> , 2013, 8, 321-328. | 0.4 | 0 |
| 173 | Lipoprotein(a) Measurement in Clinical Practice. <i>JAMA Internal Medicine</i> , 2021, 181, 1138. | 5.1 | 0 |
| 174 | In vivo glycocalyx degradation induces proteinuria and insulin resistance without affecting atherogenesis in apoE knockout mice on a Western-type diet. <i>FASEB Journal</i> , 2009, 23, 950.5. | 0.5 | 0 |
| 175 | Response to: Correspondence on "Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis" by Pantelidis et al. <i>Heart</i> , 2022, 108, 576-577. | 2.9 | 0 |